Ibrutinib: the home run for cure in CLL?
- PMID: 31072960
- DOI: 10.1182/blood-2019-03-901090
Ibrutinib: the home run for cure in CLL?
Conflict of interest statement
Conflict-of-interest disclosure: C.-M.W. reported research funding and/or honoraria for a consultancy/advisory role from Hoffmann-La Roche, Janssen, AbbVie, Gilead, Celgene, Novartis, MorphoSys, and AstraZeneca.
Comment on
-
Long-term follow-up of the RESONATE phase 3 trial of ibrutinib vs ofatumumab.Blood. 2019 May 9;133(19):2031-2042. doi: 10.1182/blood-2018-08-870238. Epub 2019 Mar 6. Blood. 2019. PMID: 30842083 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources

